A mutant protein of SaCas12i nuclease with enhanced activity and its application

By optimizing the structure of the SaCas12i nuclease and designing crRNA, a 7M-Cas12i fusion protein was developed, overcoming the limitations of the CRISPR/Cas9 system in plant breeding and achieving highly efficient gene editing, especially significantly improving genome editing efficiency in maize.

CN123063379APending Publication Date: 2026-11-10INSTITUTE OF CROP SCIENCE CHINESE ACADEMY OF AGRICULTURAL SCIENCES
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611586581.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-10-14
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

The existing CRISPR/Cas9 system has limitations in gene editing due to its large molecular weight, strong PAM restriction, tendency to produce blunt end repair, and high off-target risk. These limitations restrict its application in multi-target editing, precise site editing, and modification of complex genome segments, especially in the field of plant breeding.

Method used

By performing seven point mutations on the SaCas12i nuclease, a 7M-Cas12i fusion protein was developed, including mutations such as A182R, K215R, S220R, D384R, A442R, Q751E, and V753I, to enhance its gene editing activity. Combined with optimized crRNA design, this enabled efficient recognition of TTV-type PAM sites and efficient knockout of endogenous maize genes.

Benefits of technology

It significantly improved the genome editing efficiency of SaCas12i nuclease in maize protoplasts, broadened its application scenarios in maize molecular breeding and gene function research, and achieved efficient knockout and editing of maize endogenous genes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

This invention discloses a mutant protein of SaCas12i nuclease with enhanced activity and its applications. The invention provides a protein characterized by being either (I) or (II) the following: (I) the protein shown in SEQ ID NO: 3; (II) a fusion protein having the protein shown in SEQ ID NO: 3. The protein shown in SEQ ID NO: 3 is the 7M-Cas12i nuclease. Compared to the wild-type SaCas12i nuclease, the 7M-Cas12i nuclease exhibits significantly improved gene editing efficiency.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biotechnology, specifically the field of gene editing, and relates to a SaCas12i nuclease mutant protein with enhanced activity and its applications. Background Technology

[0002] CRISPR / Cas (Clustered Regularly Interspaced Short Palindromic Repeats / CRISPR-associated protein) technology is a precision gene editing technology derived from the acquired immune system of bacteria and archaea. This technology utilizes CRISPR-RNA (crRNA) or single guide RNA (sgRNA) to guide Cas nucleases to recognize specific DNA sequences and produce targeted cutting or base alterations at the target site, thereby achieving functions such as gene knockout, gene insertion, sequence substitution, and gene expression regulation. From early Cas9-mediated DNA cutting editing to ABE / CBE base editing and Prime Editing precision editing derivative technologies, this technology has continuously improved its editing accuracy and application scope. Currently, CRISPR / Cas technology has become an important tool for functional genomics research and crop genetic improvement, providing new technical approaches for breeding high-yielding, high-quality, stress-resistant, and herbicide-resistant new varieties.

[0003] CRISPR / Cas systems can be divided into two main categories (Class 1 and Class 2) based on the structure and function of Cas proteins. Class 2 systems mainly include Type II, Type V, and Type VI. The CRISPR / Cas9 system is the most commonly used type II CRISPR system. It recognizes the 3'-NGG PAM motif and performs blunt-end cleavage of the target sequence, making it the most widely used system currently. CRISPR / Cas Type V systems are a novel RNA-guided DNA editing technology distinct from Cas9. Representative members Cas12a, Cas12b, and Cas12i possess unique PAM recognition mechanisms, RuvC single nuclease structures, and broad genome targeting capabilities. Among these, the Cas12i protein, due to its smaller molecular weight (approximately 1000 aa, compared to approximately 1368 aa for SpCas9), its 5'-TTN-PAM recognition characteristics, and its excellent engineering potential, is widely used in the development of next-generation gene knockout and precise base editing tools. Especially in the field of plant molecular breeding, Cas12i can overcome the PAM limitation of the Cas9 system, has a smaller molecular weight, is more suitable for viral vector delivery, and is easier to modify for protein engineering, providing new technical approaches for improving the resistance, yield and quality of crops such as rice and corn.

[0004] The development of CRISPR / Cas technology relies on continuous optimization of Cas protein editing activity, target specificity, PAM recognition range, protein size, and delivery efficiency. In recent years, researchers have obtained a series of performance-enhanced Cas protein variants through strategies such as protein engineering, structure-guided design, directed evolution, and artificial intelligence-assisted design, significantly expanding the application scope of gene editing tools.

[0005] The most widely used SpCas9 system currently recognizes NGG-type PAM sequences. While it offers high editing efficiency, it suffers from drawbacks such as large molecular weight, strong PAM restriction, susceptibility to blunt-end repair, and a relatively high off-target risk, limiting its application in multi-target editing, precise site editing, and complex genomic region modification. In contrast, the V-type CRISPR-Cas12i family of nucleases offers significant advantages, including smaller protein molecular weight, more compact structure, lower expression burden, recognition of AT-rich NTTN loose PAMs, sticky cleavage, and lower off-target rates, making it a promising candidate for precision gene editing in crops.

[0006] With the deepening research on the CRISPR / Cas Type V system, Cas12i, due to its unique structural characteristics and targeting properties, has gradually become an important gene editing tool following Cas9 and Cas12a. However, natural Cas12i proteins often suffer from low editing activity, insufficient targeting efficiency, and limited adaptability to different species. Therefore, optimizing the structure and editing performance of Cas12i proteins and developing engineered Cas12i proteins with high activity, high specificity, and broad applicability is of great significance for expanding the CRISPR editing tool system and promoting precision breeding. It can overcome the limitations of the traditional Cas9 system in PAM recognition, target coverage, and delivery capabilities, and build a more efficient, flexible, and precise new gene editing platform. Especially in the field of precision plant breeding, highly active Cas12i and its derived base editing systems can achieve targeted modification of important agronomic genes, providing new tools for breeding high-yield, high-quality, stress-resistant, and herbicide-resistant new varieties of crops such as rice, maize, and wheat. Summary of the Invention

[0007] The purpose of this invention is to provide a SaCas12i nuclease mutant protein with enhanced activity and its applications.

[0008] This invention provides a protein, characterized in that: the protein is as follows (I) or (II): (I) The protein shown in SEQ ID NO: 3; (II) A fusion protein having the protein shown in SEQ ID NO: 3.

[0009] The protein shown in SEQ ID NO: 3 is named 7M-Cas12i nuclease.

[0010] The fusion protein having the protein shown in SEQ ID NO: 3 is named 7M-Cas12i fusion protein.

[0011] Specifically, the 7M-Cas12i fusion protein consists of the following segments from upstream to downstream: the segment shown in SEQ ID NO: 11, the segment shown in SEQ ID NO: 3, and the segment shown in SEQ ID NO: 12.

[0012] The present invention also provides a biomaterial, characterized in that: the biomaterial is any one of the following (a1) to (a6): (a1) The nucleic acid molecule encoding the protein; (a2) A DNA molecule having the nucleic acid molecule described in (a1); (a3) An expression cassette having the nucleic acid molecule described in (a1); (a4) A recombinant vector having the nucleic acid molecule described in (a1); (a5) A recombinant vector having the DNA molecule described in (a2); (a6) A recombinant vector having the expression cassette described in (a3).

[0013] Specifically, the nucleic acid molecule encoding the 7M-Cas12i nuclease is the DNA molecule encoding the 7M-Cas12i nuclease, also known as the 7M-Cas12i gene.

[0014] Specifically, the nucleic acid molecule encoding the 7M-Cas12i fusion protein is the DNA molecule encoding the 7M-Cas12i fusion protein, also known as the 7M-Cas12i fusion gene.

[0015] Specifically, the 7M-Cas12i gene is shown in SEQ ID NO: 4.

[0016] Specifically, the 7M-Cas12i fusion gene consists of the following segments from upstream to downstream: the segment shown in positions 10732-10851 of SEQ ID NO: 5, the segment shown in SEQ ID NO: 4, and the segment shown in positions 13993-14043 of SEQ ID NO: 5.

[0017] Specifically, the DNA molecule having the nucleic acid molecule described in (a1) is composed of the following segments from upstream to downstream: the segment shown in positions 8695-10851 of SEQ ID NO: 5, the segment shown in SEQ ID NO: 4, and the segment shown in positions 13993-14319 of SEQ ID NO: 5.

[0018] Specifically, the expression cassette containing the nucleic acid molecule described in (a1) sequentially comprises the following elements: a promoter, a 7M-Cas12i gene, and a terminator. Specifically, the promoter is the ZmUbi-1 promoter. Specifically, the terminator is the NOS terminator. Specifically, the expression cassette containing the nucleic acid molecule described in (a1) is composed of the following segments sequentially from upstream to downstream: the segment shown in positions 8695-10851 of SEQ ID NO: 5, the segment shown in position 4 of SEQ ID NO: 5, and the segment shown in positions 13993-14319 of SEQ ID NO: 5.

[0019] Specifically, the recombinant vector having the nucleic acid molecule described in (a1) is a recombinant vector obtained by replacing positions 10852-13992 of the vector shown in SEQ ID NO: 5 with SEQ ID NO: 4. Specifically, the recombinant vector having the nucleic acid molecule described in (a1) is a recombinant vector obtained by replacing positions 10852-13992 of the vector shown in SEQ ID NO: 5 with SEQ ID NO: 4 and replacing positions 8594-8613 of the vector shown in SEQ ID NO: 5 with a DNA molecule for transcription to obtain a spacer targeting the target gene.

[0020] This invention also protects the use of the protein or the biomaterial in the preparation of products for plant gene editing.

[0021] This invention also protects the use of the protein or the biological material in plant gene editing.

[0022] The present invention also protects a recombinant vector, characterized in that: the recombinant vector has the following elements: a DNA molecule encoding the protein, and a DNA molecule for transcription to obtain crRNA; the DNA corresponding to the direct repeat sequence of the crRNA is shown in SEQ ID NO: 7.

[0023] Specifically, the DNA molecule encoding the protein is shown in SEQ ID NO: 4.

[0024] Specifically, the DNA molecule encoding the protein is composed of the following segments from upstream to downstream: the segment shown in positions 10732-10851 of SEQ ID NO: 5, the segment shown in SEQ ID NO: 4, and the segment shown in positions 13993-14043 of SEQ ID NO: 5.

[0025] Specifically, the DNA molecule encoding the protein is composed of the following segments from upstream to downstream: the segment shown in positions 8695-10851 of SEQ ID NO: 5, the segment shown in SEQ ID NO: 4, and the segment shown in positions 13993-14319 of SEQ ID NO: 5.

[0026] Specifically, crRNA consists of the following elements: direct repeat sequences and spacers.

[0027] Specifically, the DNA molecule used to transcribe crRNA consists of the following elements: a DNA molecule used to transcribe direct repetitive sequences and a DNA molecule used to transcribe a spacer that targets the target gene.

[0028] DNA molecules used for transcription to obtain direct repeat sequences are shown in SEQ ID NO: 7.

[0029] DNA molecules used for transcription to obtain direct repeat sequences are shown in positions 8571-8593 of SEQ ID NO: 5.

[0030] Specifically, the DNA molecule used for transcription to obtain crRNA consists of the following elements: the DNA molecule shown in positions 8528-8570 of SEQ ID NO: 5, the DNA molecule used for transcription to obtain direct repeat sequences, the DNA molecule used for transcription to obtain a spacer targeting the target gene, and the DNA molecule shown in positions 8614-8681 of SEQ ID NO: 5.

[0031] Specifically, the DNA molecule used for transcription to obtain crRNA consists of the following elements: the DNA molecule shown in positions 8130-8570 of SEQ ID NO: 5, the DNA molecule used for transcription to obtain direct repeat sequences, the DNA molecule used for transcription to obtain a spacer targeting the target gene, and the DNA molecule shown in positions 8614-8688 of SEQ ID NO: 5.

[0032] Specifically, the recombinant vector is obtained by replacing positions 10852-13992 of the vector shown in SEQ ID NO: 5 with SEQ ID NO: 4. Specifically, the recombinant vector is obtained by replacing positions 10852-13992 of the vector shown in SEQ ID NO: 5 with SEQ ID NO: 4 and replacing positions 8594-8613 of the vector shown in SEQ ID NO: 5 with a DNA molecule for transcription to obtain a spacer targeting the target gene.

[0033] This invention also protects the use of the recombinant vector in the preparation of products for plant gene editing.

[0034] This invention also protects the application of the recombinant vector in plant gene editing.

[0035] This invention also provides a method for improving the gene editing activity of SaCas12i nuclease, comprising the following steps: subjecting the wild-type SaCas12i nuclease to the following seven point mutations: amino acid residue 182 is mutated from alanine to arginine, amino acid residue 215 is mutated from lysine to arginine, amino acid residue 220 is mutated from serine to arginine, amino acid residue 384 is mutated from aspartic acid to arginine, amino acid residue 442 is mutated from alanine to arginine, amino acid residue 751 is mutated from glutamine to glutamic acid, and amino acid residue 753 is mutated from valine to isoleucine; the wild-type SaCas12i nuclease is shown in SEQ ID NO: 1. The gene editing activity of the mutated nuclease is higher than that of the wild-type SaCas12i nuclease.

[0036] Specifically, the method involves the following steps: seven point mutations are performed on the gene encoding the wild-type SaCas12i nuclease: A182R, K215R, S220R, D384R, A442R, Q751E, and V753I; the wild-type SaCas12i nuclease is as shown in SEQ ID NO. NO: 1; A182R refers to the mutation of the codon encoding the 182nd amino acid residue of the wild-type SaCas12i nuclease from the codon encoding alanine to the codon encoding arginine (specifically, from GCC to CGG); K215R refers to the mutation of the codon encoding the 215th amino acid residue of the wild-type SaCas12i nuclease from the codon encoding lysine to the codon encoding arginine (specifically, from AAG to CGG); S220R refers to the mutation of the codon encoding the 220th amino acid residue of the wild-type SaCas12i nuclease from the codon encoding serine to the codon encoding arginine (specifically, from TCT to CGG); D384R refers to the mutation of the codon encoding the 384th amino acid residue of the wild-type SaCas12i nuclease... The codons for wild-type SaCas12i nuclease are mutated from the codon encoding aspartic acid to the codon encoding arginine (specifically, from GAC to CGG); A442R refers to the mutation of the codon encoding the 442nd amino acid residue of wild-type SaCas12i nuclease from the codon encoding alanine to the codon encoding arginine (specifically, from GCT to CGG); Q751E refers to the mutation of the codon encoding the 751st amino acid residue of wild-type SaCas12i nuclease from the codon encoding glutamine to the codon encoding glutamate (specifically, from CAG to GAG); V753I refers to the mutation of the codon encoding the 753rd amino acid residue of wild-type SaCas12i nuclease from the codon encoding valine to the codon encoding isoleucine (specifically, from GTT to ATC). The gene encoding the wild-type SaCas12i nuclease is shown in SEQ ID NO: 2. The gene editing activity of the mutated nuclease is higher than that of the wild-type SaCas12i nuclease.

[0037] Specifically, the gene editing is based on the CRISPR / Cas Type V system.

[0038] Specifically, the gene editing is gene editing based on the Cas12i nuclease of the CRISPR / Cas Type V system.

[0039] Specifically, the gene editing refers to gene editing targeting plants.

[0040] Specifically, the plant is a monocotyledonous or dicotyledonous plant. Specifically, the plant is a member of the Poaceae family. Specifically, the plant is a member of the genus *Zea*. Specifically, the plant is corn, for example, corn B73.

[0041] Any of the products mentioned above are reagents or kits.

[0042] For example, the target gene is the ZmWX gene, the ZmBr2 gene, or the Zmglossy gene.

[0043] The GeneID of the ZmWX gene is 541854. The ZmWX gene corresponds to positions 25126885-25130560 in NCBI Reference Sequence: NC_050104.1 (20-FEB-2025). The protein corresponding to the ZmWX gene is NP_001358937.1 (22-JUN-2025). The mRNA corresponding to the ZmWX gene is NM_001372008.1 (22-JUN-2025).

[0044] The GeneID of the ZmBr2 gene is 100384057. The ZmBr2 gene corresponds to positions 206626935-206634024 in NCBI Reference Sequence: NC_050096.1 (20-FEB-2025). The protein corresponding to the ZmBr2 gene is NCBI Reference Sequence: NP_001349170.1 (30-APR-2021). The mRNA corresponding to the ZmBr2 gene is NCBI Reference Sequence: NM_001362241.1 (30-APR-2021).

[0045] The GeneID of the Zmglossy gene is 100280692. The Zmglossy gene corresponds to positions 194359771-194363948 in NCBI Reference Sequence: NC_050100.1 (20-FEB-2025). The protein corresponding to the Zmglossy gene is NCBI Reference Sequence: NP_001147083.1 (03-SEP-2021). The mRNA corresponding to the Zmglossy gene is NCBI Reference Sequence: NM_001153611.1 (03-SEP-2021). The protein corresponding to the Zmglossy gene is NCBI Reference Sequence: XP_008643572.1 (20-FEB-2025). The mRNA corresponding to the Zmglossy gene is NCBI Reference Sequence: XM_008645350.2 (20-FEB-2025).

[0046] For example, when the target gene is the ZmWX gene, the target sequence of the crRNA is shown in SEQ ID NO: 8. The DNA molecule used for transcription to obtain the spacer targeting the target gene is shown in positions 4-23 of SEQ ID NO: 8.

[0047] For example, when the target gene is the ZmBr2 gene, the target sequence of the crRNA is shown in SEQ ID NO: 9. The DNA molecule used for transcription to obtain the spacer targeting the target gene is shown in positions 4-23 of SEQ ID NO: 9.

[0048] For example, when the target gene is the Zmglossy gene, the target sequence of the crRNA is shown in SEQ ID NO: 10. The DNA molecule used for transcription to obtain the spacer targeting the target gene is shown in positions 4-23 of SEQ ID NO: 10.

[0049] Compared to the wild-type SaCas12i nuclease, the 7M-Cas12i nuclease significantly improves genome editing efficiency in maize protoplasts, can recognize TTV-type PAM sites, and achieves efficient knockout of endogenous maize genes, thus broadening the application scenarios of Cas12i nuclease in maize molecular breeding and gene function research. The mutant protein, expression vector, and editing method provided by this invention can be directly used for crop germplasm creation and genetic improvement. Attached Figure Description

[0050] Figure 1 This is a result diagram of Example 2.

[0051] Figure 2 This is a result diagram of Example 3.

[0052] Figure 3 This is a result diagram of Example 4.

[0053] Figure 4 This is a result diagram of Example 5. Detailed Implementation

[0054] The present invention will now be described in further detail with reference to specific embodiments. The given embodiments are merely illustrative of the invention and not intended to limit its scope. The embodiments provided below can serve as a guide for further improvements by those skilled in the art and do not constitute a limitation on the invention in any way.

[0055] Unless otherwise specified, the experimental methods used in the following embodiments are conventional methods, performed according to the techniques or conditions described in the literature in this field or according to the product instructions. Unless otherwise specified, the materials and reagents used in the following embodiments are commercially available. Unless otherwise specified, the quantitative experiments in the following embodiments are all performed in triplicate, and the results are averaged.

[0056] Amino acid residues can be represented by a single letter or a three-letter symbol, for example: alanine (Ala, A), valine (Val, V), glycine (Gly, G), leucine (Leu, L), glutamine (Gln, Q), phenylalanine (Phe, F), tryptophan (Trp, W), tyrosine (Tyr, Y), aspartic acid (Asp, D), asparagine (Asn, N), glutamic acid (Glu, E), lysine (Lys, K), methionine (Met, M), serine (Ser, S), threonine (Thr, T), cysteine ​​(Cys, C), proline (Pro, P), isoleucine (Ile, I), histidine (His, H), and arginine (Arg, R).

[0057] The wild-type SaCas12i nuclease (also known as WT-Cas12i nuclease) is shown in SEQ ID NO: 1, and its encoding gene is shown in SEQ ID NO: 2. The mutant SaCas12i nuclease (also known as 7M-Cas12i nuclease) obtained by this invention is shown in SEQ ID NO: 3, and its encoding gene is shown in SEQ ID NO: 4.

[0058] The plasmid crRNA (E-DR / Zmwx-Spacer)-WTCas12i is shown in SEQ ID NO: 5. In SEQ ID NO: 5: positions 8571-8613 are used for transcription to form crRNA (the DNA molecule transcribed to form E-DR corresponds to positions 8571-8593 in SEQ ID NO: 5, this segment is the same as SEQ ID NO: 7; the DNA molecule transcribed to form Spacer corresponds to positions 8594-8613 in SEQ ID NO: 5, this segment is the same as positions 4-23 in SEQ ID NO: 8), and positions 10732-14043 encode the fusion protein (the DNA molecule encoding WT-Cas12i nuclease corresponds to positions 10852-13992 in SEQ ID NO: 5, this segment is the same as SEQ ID NO: 2). The fusion protein consists of the following segments from upstream to downstream: the segment shown in SEQ ID NO: 11 (containing 3×Flag and NLS), the segment shown in SEQ ID NO: 1 (WT-Cas12i nuclease), and the segment shown in SEQ ID NO: 12 (containing NLS). The target sequence of the crRNA is shown in SEQ ID NO: 8 (located in the ZmWX gene).

[0059] W5 buffer: Contains 125 mM CaCl2, 5 mM KCl, 154 mM NaCl, and 2 mM MES, with the balance being water; filtered through a 0.45 μm pore size membrane and stored at 4°C for later use. WI-Ca 2+ Solution: Contains 0.5M mannitol, 100mM KCl, 4mM MES, and 100mM CaCl2, with the balance being water; filtered through a 0.45μm pore size membrane and stored at 4℃ for later use. (Mmg-Ca) 2+ Solution: Contains 0.4M mannitol, 7.5mM MgCl2, 4mM MES, and 100mM CaCl2, with the balance being water; filtered through a 0.45μm pore size membrane and stored at 4℃ for later use. 40% PEG4000-Ca 2+Solution: Contains 0.2M mannitol, 0.1M CaCl2, and 40g / 100mL pEG4000, with the remainder being water; filter through a 0.45μm pore size membrane and store at 4℃ for later use. Preparation of enzymatic hydrolysate: 10mL of 0.8M mannitol aqueous solution, 0.2mL of 1M KCl aqueous solution, 2mL of 0.2M MES aqueous solution, 0.3g of cellulase (Cellulase R10), and 0.08g of macrozyme (Macerozyme R10), add ddH2O to 20mL, mix well, then place in a 55℃ water bath for 10min, cool naturally to room temperature, then add BSA and calcium chloride (to make the BSA concentration 0.1g / 100ml and the CaCl2 concentration 10mM); filter through a 0.45μm pore size membrane and store at 4℃ for later use.

[0060] Example 1: Method for detecting genetic transformation efficiency I. Preparation of maize protoplasts Corn B73 was sown and cultured in the dark, resulting in etiolated seedlings. The second true leaf of each etiolated seedling was taken, and the middle portion was cut into 1mm wide strips. These leaf strips were placed in a 100mL volumetric beaker containing 20mL of enzymatic hydrolysate. The mixture was first shaken at 28℃ and 40-50rpm for 3-4 hours in the dark, then shaken at 80rpm for 5 minutes in the dark. The mixture was then filtered through a 200-mesh nylon cloth, and the filtrate was collected. The filtrate was centrifuged at 100g for 2 minutes, and the supernatant was discarded. The remaining precipitate was the protoplast.

[0061] Resuspend protoplasts in W5 buffer pre-chilled at 4°C, then centrifuge at 100g for 1 min, discard the supernatant, resuspend in fresh W5 buffer pre-chilled at 4°C, then incubate on ice for 30 min, then centrifuge at 100g for 1 min, discard the supernatant, and resuspend in fresh W5 buffer pre-chilled at 4°C. 2+ The protoplasts were resuspended in the solution and their density was adjusted to 5 × 10⁻⁶. 5 The concentration of protoplasts per mL is the protoplast suspension, which should be kept on ice for later use.

[0062] II. Transformation of Maize Protoplasts Take a 2 mL centrifuge tube, add 20 μL of the test plasmid solution (plasmid DNA content is 20 μg) and 200 μL of the protoplast suspension prepared in step one, and gently tap to mix. Then, add 220 μL of 40% PEG4000-Ca to the centrifuge tube. 2+ Mix the solution gently by vortexing and incubate at room temperature for 18 min. Then, add 880 μL of W5 buffer to the centrifuge tube to terminate the reaction, centrifuge at 100 g for 3 min, and discard the supernatant. Next, add 1 mL of W5 buffer to the centrifuge tube, vortex to mix, centrifuge at 100 g for 1 min, and discard the supernatant. Finally, add 1 mL of WI-Ca to the centrifuge tube.2+ The solution was incubated in the dark at room temperature for 48 hours.

[0063] III. Editing Efficiency Test After completing step two, centrifuge at 100g for 1 minute, discard the supernatant, and the remaining precipitate is the protoplast. Take the protoplast, extract genomic DNA, and perform PCR amplification using the genomic DNA as a template. After recovering the amplification product, perform high-throughput sequencing (Hi-Tom) and calculate the editing efficiency. Editing efficiency = the percentage of mutated sequences out of the total number of sequenced sequences. Mutated sequences refer to sequences different from the reference sequence. The reference sequence refers to the sequencing result of the amplification product obtained by PCR amplification using the same primers as the genomic DNA of the protoplast prepared in step one.

[0064] When the target gene is the ZmWX gene, the primer pairs used for PCR amplification are as follows: Upstream primer (SEQ ID NO: 13): 5'-AGCAGTATACACTGATGAGA-3'; Downstream primer (SEQ ID NO: 14): 5'-GAAGATTCTCGAGCTCAACAG-3'.

[0065] When the target gene is the ZmBr2 gene, the primer pairs used for PCR amplification are as follows: Upstream primer (SEQ ID NO: 15): 5'-CATCATCTACCTCCCAAGGC-3'; Downstream primer (SEQ ID NO: 16): 5'-GGTGCAGTTTGGTCCGTCT-3'.

[0066] When the target gene is the Zmglossy gene, the primer pairs used for PCR amplification are as follows: Upstream primer (SEQ ID NO: 17): 5'-TACGAGAGCGGCAGGACGCA-3'; Downstream primer (SEQ ID NO: 18): 5'-CTAACGCAGAGAAACCAACC-3'.

[0067] Example 2: Optimization of the crRNA backbone The crRNA that matches the Cas12i nuclease consists of a direct repeat sequence (DR) and a spacer sequence. The DR is responsible for binding to the Cas12i nuclease, while the spacer is responsible for recognizing and binding to the target DNA. The DR contains a stem-loop structure, which is crucial for protein binding. The DNA molecule corresponding to the unoptimized DR (WT-DR) is shown in SEQ ID NO: 6, and the DNA molecule corresponding to the optimized DR (E-DR) is shown in SEQ ID NO: 7.

[0068] Plasmid I-1 and plasmid I-2 were prepared separately. Both plasmid I-1 and plasmid I-2 are circular plasmids formed from double-stranded DNA molecules. Compared with plasmid crRNA (E-DR / Zmwx-Spacer)-WTCas12i, plasmid I-1 differs only in that the DNA molecule transcribed to form the Spacer targeting the ZmWX gene is replaced with the DNA molecule transcribed to form the ZmBr2 gene (i.e., positions 8594-8613 in SEQ ID NO: 5 are replaced with positions 4-23 in SEQ ID NO: 9), and the DNA molecule transcribed to form E-DR is replaced with the DNA molecule transcribed to form WT-DR (i.e., positions 8571-8593 in SEQ ID NO: 5 are replaced with SEQ ID NO: 6). Compared to plasmid crRNA (E-DR / Zmwx-Spacer)-WTCas12i, plasmid I-2 differs only in that the DNA molecule transcribed to form a Spacer targeting the ZmWX gene is replaced with the DNA molecule transcribed to form a Spacer targeting the ZmBr2 gene (i.e., positions 8594-8613 in SEQ ID NO: 5 are replaced with positions 4-23 in SEQ ID NO: 9). The target sequences of plasmids I-1 and I-2 are shown in SEQ ID NO: 9 (located in the ZmBr2 gene). The only difference between plasmids I-1 and I-2 is that the crRNA transcribed from plasmid I-1 has the unoptimized DR (WT-DR), while the crRNA transcribed from plasmid I-2 has the optimized DR (E-DR).

[0069] Plasmid I-1 and plasmid I-2 were used as test plasmids, and the genetic transformation efficiency (target gene was ZmBr2) was tested according to the method in Example 1. Three replicate experiments were performed, and the results were taken as mean ± standard deviation.

[0070] See results Figure 1(The vertical axis represents editing efficiency, %; the bars from left to right correspond to plasmid I-1 and plasmid I-2, respectively). The genetic transformation efficiency of plasmid I-2 was significantly higher than that of plasmid I-1. The results indicate that E-DR can significantly improve genetic transformation efficiency compared to WT-DR. The editing efficiency using plasmid I-1 was 10.70% ± 0.65%, while that using plasmid I-2 was 15.95% ± 1.03%, a significant difference (P = 0.0095). These results demonstrate that E-DR can increase editing efficiency by 1.49 times compared to WT-DR.

[0071] Example 3: Optimization of SaCas12i nuclease Plasmids II-0, II-1-1, II-1-2, II-1-3, II-1-4, II-1-5, II-1-6, II-1-7, II-2-1, II-2-2, II-2-3, II-2-4, II-2-5, II-2-6, II-2-7, II-2-8, II-2-9, II-2-10, II-2-11, II-2-12, II-2-13, II-2-14, and II-2-15 were prepared. These plasmids are collectively referred to as the II series plasmids. All II series plasmids are circular plasmids formed from double-stranded DNA molecules. For the II series plasmids, the target sequence of crRNA is shown in SEQ ID NO: 9 (located in the ZmBr2 gene).

[0072] Compared to plasmid crRNA (E-DR / Zmwx-Spacer)-WTCas12i, plasmid II-0 differs only in that the DNA molecule that transcribes to form a Spacer targeting the ZmWX gene is replaced with the DNA molecule that transcribes to form a Spacer targeting the ZmBr2 gene (i.e., positions 8594-8613 in SEQ ID NO: 5 are replaced with positions 4-23 in SEQ ID NO: 9).

[0073] Compared with plasmid crRNA (E-DR / Zmwx-Spacer)-WTCas12i, the differences between plasmids II-1-1 to II-1-7 and plasmids II-2-1 to II-2-15 are only that: the DNA molecule that transcribes to form a Spacer targeting the ZmWX gene is replaced with the DNA molecule that transcribes to form a Spacer targeting the ZmBr2 gene (that is, positions 8594-8613 in SEQ ID NO: 5 are replaced with positions 4-23 in SEQ ID NO: 9) and the DNA molecule encoding the wild-type SaCas12i nuclease is replaced with the DNA molecule encoding the mutant SaCas12i nuclease.

[0074] Plasmid II-0 contains the gene encoding the wild-type SaCas12i nuclease. Plasmid II-1-1 contains the gene encoding the A182R mutant SaCas12i nuclease. Plasmid II-1-2 contains the gene encoding the K215R mutant SaCas12i nuclease. Plasmid II-1-3 contains the gene encoding the S220R mutant SaCas12i nuclease. Plasmid II-1-4 contains the gene encoding the A182R+S220R mutant SaCas12i nuclease. Plasmid II-1-5 contains the gene encoding the A182R+K215R mutant SaCas12i nuclease. Plasmid II-1-6 contains the gene encoding the K215R+S220R mutant SaCas12i nuclease. Plasmid II-1-7 contains the gene encoding the A182R+K215R+S220R mutant SaCas12i nuclease. Plasmid II-2-1 contains the gene encoding the D384R mutant SaCas12i nuclease. Plasmid II-2-2 contains the gene encoding the A442R mutant SaCas12i nuclease. Plasmid II-2-3 contains the gene encoding the Q751E mutant SaCas12i nuclease. Plasmid II-2-4 contains the gene encoding the V753I mutant SaCas12i nuclease. Plasmid II-2-5 contains the gene encoding the D384R+A442R mutant SaCas12i nuclease. Plasmid II-2-6 contains the gene encoding the D384R+Q751E mutant SaCas12i nuclease. Plasmid II-2-7 contains the gene encoding the D384R+V753I mutant SaCas12i nuclease. Plasmid II-2-8 contains the gene encoding the A442R+Q751E mutant SaCas12i nuclease. Plasmid II-2-9 contains the gene encoding the A442R+V753I mutant SaCas12i nuclease. Plasmid II-2-10 contains the gene encoding the Q751E+V753I mutant SaCas12i nuclease. Plasmid II-2-11 contains the gene encoding the D384R+A442R+Q751E mutant SaCas12i nuclease. Plasmid II-2-12 contains the gene encoding the D384R+A442R+V753I mutant SaCas12i nuclease. Plasmid II-2-13 contains the gene encoding the D384R+Q751E+V753I mutant SaCas12i nuclease. Plasmid II-2-14 contains the gene encoding the A442R+Q751E+V753I mutant SaCas12i nuclease. Plasmid II-2-15 contains the gene encoding the D384R+A442R+Q751E+V753I mutant SaCas12i nuclease.

[0075] The amino acid and nucleotide mutations corresponding to various mutant types are shown in Table 1.

[0076]

[0077] The SaCas12i nucleases corresponding to each plasmid are shown in Table 2.

[0078]

[0079] Each of the II series plasmids was used as the test plasmid, and the genetic transformation efficiency (target gene was ZmBr2 gene) was detected according to the method in Example 1. Three replicate experiments were performed, and the results were taken as mean ± standard deviation.

[0080] See results Figure 2 (The vertical axis represents editing efficiency, %; the bars from left to right correspond to plasmids II-0, II-1-1 to II-1-7, and II-2-1 to II-2-15, respectively) and Table 3. Plasmids II-1-7, II-2-8, II-2-10, II-2-13, and II-2-15 had the highest editing efficiency, with P-values ​​relative to the editing efficiency of plasmid II-0 of 0.0017, 0.0007, 0.0016, 0.0006, and 0.0005, respectively. The results showed that, compared with the wild-type SaCas12i nuclease, the A182R+K215R+S220R mutant SaCas12i nuclease, A442R+Q751E mutant SaCas12i nuclease, Q751E+V753I mutant SaCas12i nuclease, D384R+Q751E+V753I mutant SaCas12i nuclease, and D384R+A442R+Q751E+V753I mutant SaCas12i nuclease could increase the editing efficiency by 2.48 times, 2.98 times, 2.76 times, 3.21 times, and 3.69 times, respectively.

[0081]

[0082] Example 4: Further optimization of SaCas12i nuclease Plasmids III-0, III-1, III-2, III-3, III-4, and III-5 were prepared separately. These plasmids are collectively referred to as the III series plasmids. All III series plasmids are circular plasmids formed from double-stranded DNA molecules. For the III series plasmids, the target sequence of crRNA is shown in SEQ ID NO: 9 (located in the ZmBr2 gene).

[0083] Compared to plasmid crRNA (E-DR / Zmwx-Spacer)-WTCas12i, plasmid III-0 differs only in that the DNA molecule that transcribes to form a Spacer targeting the ZmWX gene is replaced with the DNA molecule that transcribes to form a Spacer targeting the ZmBr2 gene (i.e., positions 8594-8613 in SEQ ID NO: 5 are replaced with positions 4-23 in SEQ ID NO: 9).

[0084] Compared with plasmid crRNA (E-DR / Zmwx-Spacer)-WTCas12i, plasmids III-1 to III-5 differ only in that: the DNA molecule that transcribes to form a Spacer targeting the ZmWX gene is replaced with the DNA molecule that transcribes to form a Spacer targeting the ZmBr2 gene (i.e., positions 8594-8613 in SEQ ID NO: 5 are replaced with positions 4-23 in SEQ ID NO: 9) and the DNA molecule encoding the wild-type SaCas12i nuclease is replaced with the DNA molecule encoding the mutant SaCas12i nuclease.

[0085] Plasmid III-0 contains the gene encoding the wild-type SaCas12i nuclease. Plasmid III-1 contains the gene encoding the A182R+K215R+S220R mutant SaCas12i nuclease. Plasmid III-2 contains the gene encoding the A182R+K215R+S220R+A442R+Q751E mutant SaCas12i nuclease. Plasmid III-3 contains the gene encoding the A182R+K215R+S220R+Q751E+V753I mutant SaCas12i nuclease. Plasmid III-4 contains the gene encoding the A182R+K215R+S220R+D384R+Q751E+V753I mutant SaCas12i nuclease. Plasmid III-5 contains a gene encoding the mutant SaCas12i nuclease A182R+K215R+S220R+D384R+A442R+Q751E+V753I.

[0086] The amino acid and nucleotide mutations corresponding to various mutant types are shown in Table 1.

[0087] The SaCas12i nucleases corresponding to each plasmid are shown in Table 4.

[0088]

[0089] Each of the III series plasmids was used as the test plasmid, and the genetic transformation efficiency (target gene was ZmBr2 gene) was detected according to the method in Example 1. Three replicate experiments were performed, and the results were taken as mean ± standard deviation.

[0090] See results Figure 3 (The vertical axis represents editing efficiency, %; the bars from left to right correspond to plasmids III-0, III-1, III-2, III-3, III-4, and III-5, respectively) and Table 5. The p-values ​​of the editing efficiencies of plasmids III-1, III-2, III-3, III-4, and III-5 relative to plasmid III-0 are 0.0029, 0.0011, <0.0001, <0.0001, and <0.0001, respectively. The results showed that, compared to the wild-type SaCas12i nuclease, the mutant SaCas12i nucleases A182R+K215R+S220R+A442R+Q751E, A182R+K215R+S220R+Q751E+V753I, and A182R+K215R+S220R+... The D384R+Q751E+V753I mutant SaCas12i nuclease and the A182R+K215R+S220R+D384R+A442R+Q751E+V753I mutant SaCas12i nuclease can increase editing efficiency by 2.10 times, 2.41 times, 3.57 times, 3.70 times, and 3.82 times, respectively.

[0091] The mutant SaCas12i nuclease with the highest editing efficiency, A182R+K215R+S220R+D384R+A442R+Q751E+V753I, has been renamed 7M-Cas12i nuclease. The 7M-Cas12i nuclease is shown in SEQ ID NO: 3, and its encoding gene is shown in SEQ ID NO: 4.

[0092]

[0093] Example 5: Verifying the editing efficiency for different target genes. Plasmids IV-1-1, IV-1-2, IV-2-1, IV-2-2, IV-3-1, and IV-3-2 were prepared separately. These plasmids are collectively referred to as the IV series plasmids. All IV series plasmids are circular plasmids formed from double-stranded DNA molecules.

[0094] Plasmid IV-1-1, also known as plasmid crRNA (E-DR / Zmwx-Spacer)-WTCas12i, has its full sequence shown in SEQ ID NO: 5. Compared to plasmid IV-1-1, plasmid IV-1-2 differs only in that the gene encoding the WT-Cas12i nuclease is replaced with the gene encoding the 7M-Cas12i nuclease (i.e., positions 10852-13992 in SEQ ID NO: 5 are replaced with SEQ ID NO: 4). The target sequence of the crRNA is shown in SEQ ID NO: 8 (located in the ZmWX gene).

[0095] Compared with plasmid crRNA (E-DR / Zmwx-Spacer)-WTCas12i, plasmid IV-2-1 differs only in that the DNA molecule that transcribes to form a Spacer targeting the ZmWX gene is replaced with the DNA molecule that transcribes to form a Spacer targeting the ZmBr2 gene (i.e., positions 8594-8613 in SEQ ID NO: 5 are replaced with positions 4-23 in SEQ ID NO: 9). Compared to plasmid crRNA (E-DR / Zmwx-Spacer)-WTCas12i, plasmid IV-2-2 differs only in that the DNA molecule transcribed to form the Spacer targeting the ZmWX gene is replaced with the DNA molecule transcribed to form the ZmBr2 gene (i.e., positions 8594-8613 in SEQ ID NO: 5 are replaced with positions 4-23 in SEQ ID NO: 9), and the gene encoding the 7M-Cas12i nuclease is replaced with the gene encoding the WT-Cas12i nuclease (i.e., positions 10852-13992 in SEQ ID NO: 5 are replaced with SEQ ID NO: 4). The target sequence of the crRNA is shown in SEQ ID NO: 9 (located in the ZmBr2 gene).

[0096] Compared to plasmid crRNA (E-DR / Zmwx-Spacer)-WTCas12i, plasmid IV-3-1 differs only in that the DNA molecule that transcribes to form a Spacer targeting the ZmWX gene is replaced with the DNA molecule that transcribes to form a Spacer targeting the Zmglossy gene (i.e., positions 8594-8613 in SEQ ID NO: 5 are replaced with positions 4-23 in SEQ ID NO: 10). Compared to plasmid crRNA (E-DR / Zmwx-Spacer)-WTCas12i, plasmid IV-2-2 differs only in that the DNA molecule transcribed to form the Spacer targeting the ZmWX gene is replaced with the DNA molecule transcribed to form the Zmglossy gene (i.e., positions 8594-8613 in SEQ ID NO: 5 are replaced with positions 4-23 in SEQ ID NO: 10), and the gene encoding the 7M-Cas12i nuclease is replaced with the gene encoding the WT-Cas12i nuclease (i.e., positions 10852-13992 in SEQ ID NO: 5 are replaced with SEQ ID NO: 4). The target sequence of the crRNA is shown in SEQ ID NO: 10 (located in the Zmglossy gene).

[0097] Each of the IV series plasmids was used as the test plasmid, and the genetic transformation efficiency was detected according to the method in Example 1. The results are shown below. Figure 4 (The vertical axis represents editing efficiency, %; from left to right, adjacent bars form a group: the first group corresponds to the ZmWX gene, the second group to the ZmBr2 gene, and the third group to the Zmglossy gene) and Table 6. When the target sequence is located in the ZmWX gene, the 7M-Cas12i nuclease can improve the editing efficiency by 2.83 times compared to the WT-Cas12i nuclease. When the target sequence is located in the ZmBr2 gene, the 7M mutant SaCas12i nuclease can improve the editing efficiency by 3.09 times compared to the WT-Cas12i nuclease. When the target sequence is located in the Zmglossy gene, the 7M-Cas12i nuclease can improve the editing efficiency by 3.68 times compared to the WT-Cas12i nuclease.

[0098]

[0099] The present invention has been described in detail above. For those skilled in the art, the invention can be practiced in a wide range of ways with equivalent parameters, concentrations, and conditions without departing from its spirit and scope, and without requiring unnecessary experiments. Although specific embodiments have been given, it should be understood that further modifications can be made to the invention. In summary, according to the principles of the invention, this application is intended to include any changes, uses, or improvements to the invention, including changes made using conventional techniques known in the art that depart from the scope disclosed herein. Some of the essential features can be applied within the scope of the following appended claims.

Claims

1. A protein, characterized in that: The protein is a protein as shown in SEQ ID NO:

3.

2. Biomaterial, characterized by: The biological material is any one of (a1) to (a6) below: (a1) a nucleic acid molecule encoding the protein according to claim 1; (a2) a DNA molecule having the nucleic acid molecule according to (a1); (a3) an expression cassette having the nucleic acid molecule according to (a1); (a4) a recombinant vector having the nucleic acid molecule according to (a1); (a5) a recombinant vector having the DNA molecule according to (a2); (a6) a recombinant vector having the expression cassette according to (a3).

3. Use of a substance for the manufacture of a product for plant gene editing, characterized in that: The substance is the protein according to claim 1 or the biological material according to claim 2; and the plant is corn.

4. Use of a substance in plant genome editing, characterized in that: The substance is the protein according to claim 1 or the biological material according to claim 2; and the plant is corn.

5. A recombinant vector characterized in that: The recombinant vector has the following elements: a DNA molecule encoding the protein according to claim 1, and a DNA molecule for transcription to obtain a crRNA; the direct repeat sequence pair of the crRNA corresponds to a DNA as shown in SEQ ID NO:

7.

6. Use of a substance for the manufacture of a product for plant gene editing, characterized in that: The substance is the recombinant vector according to claim 5; and the plant is corn.

7. Use of a substance in plant genome editing, characterized in that: The substance is the recombinant vector according to claim 5; and the plant is corn.

8. A method of improving the gene editing activity of a SaCasl2i nuclease, comprising: The method comprises the following steps: a wild-type SaCas12i nuclease is subjected to the following 7-point mutations: the 182th amino acid residue is mutated from alanine to arginine, the 215th amino acid residue is mutated from lysine to arginine, the 220th amino acid residue is mutated from serine to arginine, the 384th amino acid residue is mutated from aspartic acid to arginine, the 442th amino acid residue is mutated from alanine to arginine, the 751th amino acid residue is mutated from glutamine to glutamic acid, and the 753th amino acid residue is mutated from valine to isoleucine; and the wild-type SaCas12i nuclease is as shown in SEQ ID NO: 1.